

# Clover Biopharmaceuticals, Ltd.

## 三葉草生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
(於開曼群島註冊成立的有限公司)

(Stock Code: 2197) (股份代號: 2197)

## NOTIFICATION LETTER 通知信函

September 19, 2022

Dear Non-registered Holder(s) (Note 1),

#### Clover Biopharmaceuticals, Ltd. (the "Company")

- Notification of Publication of 2022 Interim Report (the "Current Corporate Communication")

Please be informed that the English and Chinese versions of the Current Corporate Communication of the Company are available on the Company's website at <a href="www.cloverbiopharma.com">www.cloverbiopharma.com</a> and the website of Hong Kong Exchanges and Clearing Limited ("HKEX") at <a href="www.hkexnews.hk">www.hkexnews.hk</a>. You may access the Current Corporate Communication on the Company's website or by searching under "Listed Company Information" on the website of HKEX.

If you wish to receive the printed version(s) of the Current Corporate Communication and all future Corporate Communications (Note 2) of the Company, please complete the Request Form on the reverse side and return it to the Company c/o the Company's Hong Kong share registrar (the "Share Registrar"), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong, using the pre-paid postage mailing label at the bottom of the Request Form (a stamp is not required if posted in Hong Kong; otherwise, please affix an appropriate stamp). You may also send an e-mail with a scanned copy of the completed Request Form to <a href="mailto:clover.ecom@computershare.com.hk">clover.ecom@computershare.com.hk</a>. The Request Form may also be downloaded from the Company's website at <a href="mailto:www.cloverbiopharma.com">www.cloverbiopharma.com</a> or the website of HKEX at <a href="mailto:www.hkexnews.hk">www.hkexnews.hk</a>.

Should you have any queries relating to the above, please call the service hotline of the Share Registrar at (852) 2862 8688 during business hours (9:00 a.m. to 6:00 p.m., Monday to Friday, excluding Hong Kong public holidays).

By order of the Board Clover Biopharmaceuticals, Ltd. Dr. Peng LIANG Chairman of the Board

Note 1: This Letter is addressed to Non-registered Holder(s) of the shares in the Company ("Non-registered Holder" means such person or company whose shares are held in the Central Clearing and Settlement System and who has notified the Company from time to time through Hong Kong Securities Clearing Company Limited that he/she/it wishes to receive the Corporate Communications). If you have sold or transferred your shares in the Company, please disregard this Letter and the Request Form on the reverse side.

Note 2: Corporate Communications include but are not limited to (a) an annual report; (b) an interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

各位非登記持有人(附註1):

#### 三葉草生物製藥有限公司(「本公司」)

- 2022 中期報告(「本次公司通訊」)之登載通知

謹通知 閣下本公司本次公司通訊的中、英文版已於本公司網站 www.cloverbiopharma.com 及香港交易及結算所有限公司(「香港交易所」)網站www.hkexnews.hk 登載。 閣下可於本公司網站或在香港交易所網站於「上市公司公告」項下搜尋,以瀏覽本次公司通訊。

倘 閣下欲收取本公司本次公司通訊及所有日後公司通訊(Mit 2)的印刷本,請填妥本函背面的申請表,使用申請表下方的已預付郵費郵寄標籤(如在香港投寄,毋須貼上郵票;否則,請貼上適當的郵票),經本公司香港證券登記處(「**證券登記處**」),香港中央證券登記有限公司,地址爲香港灣仔皇后大道東 183 號合和中心 17M 樓,交回本公司。 閣下亦可將已填妥的申請表的掃描副本電郵至 clover.ecom@computershare.com.hk。申請表亦可於本公司網站 www.cloverbiopharma.com或香港交易所網站 www.hkexnews.hk下載。

如 閣下對上述事項有任何疑問,請於辦公時間內(星期一至星期五(香港公眾假期除外)上午9時正至下午6時正)致電 證券登記處熱線(852) 2862 8688 查詢。

> 承董事會命 三**葉草生物製藥有限公司** 董事長 **梁朋博士**

2022年9月19日

附註 1: 此為致本公司股份非登記持有人(「**非登記持有人**」指所持有的本公司股份存放於中央結算及交收系統的人士或公司,透過香港中央結算有限公司不時向本公司發出通知,表示 欲收取公司通訊)。倘 閻下已出售或轉讓所持有的本公司股份,則毋須理會本函件及背面的申請表。

附註 2: 公司通訊包括但不限於:(a) 年度報告;(b) 中期報告;(c) 會議通告;(d) 上市文件;(e) 通函;及 (f) 代表委任表格。

## Request Form 申請表

To: Clover Biopharmaceuticals, Ltd. (the "Company")

(Stock Code: 2197)

c/o Computershare Hong Kong Investor Services Limited

17M Floor, Hopewell Centre 183 Queen's Road East Wan Chai, Hong Kong

致: 三葉草生物製藥有限公司「本公司」)

(股份代號:2197)

經香港中央證券登記有限公司 香港灣仔皇后大道東 183 號 合和中心 17M 樓

I/We would like to receive the Current Corporate Communication and all future Corporate Communications\* of the Company in the manner as indicated

本人/吾等希望以下列方式收取 貴公司本次公司通訊及所有 貴公司日後之公司通訊\*:

(Please mark "X" in ONLY ONE of the following boxes) (請僅在下列其中一個空格內劃上「X」號)		
	to receive the <b>printed English version</b> ONLY; <b>OR</b> 僅收取 <b>英文印刷本</b> ; <b>或</b>	
	to receive the <b>printed Chinese version</b> ONLY; <b>OR</b> 僅收取 <b>中文印刷本</b> ; <b>或</b>	
	to receive both the <b>printed English and Chinese versions</b> . 同時收取 <b>中、英文印刷本</b> 。	
Name(a) of Nan negistaned Shanshalden(a)#		

非登記股東姓名

( Please use ENGLISH BLOCK LETTERS 請用英文正楷填寫 )

Address<sup>4</sup> 地址#

( Please use ENGLISH BLOCK LETTERS 請用英文正楷填寫 )

Contact telephone number

聯絡電話號碼

Date

簽名

日期

You are required to fill in the details if you download this Request Form from the Company's website or the website of Hong Kong Exchanges and Clearing Limited. 如 關下從本公司網站或香港交易及結算所有限公司網站下載本申請表格,務必填上有關資料。

Notes 附註:

- Unless otherwise defined herein, terms used in this Request Form shall bear the same meanings as those defined in the Letter to Non-registered Holder(s) dated September 19, 2022. 除本文另有界定外,本申請表中所用詞彙與日期為2022年9月19日致非登記持有人之函件所界定者具有相同涵義。
  This Request Form is to be completed by Non-registered Holder(s) of the shares in the Company ("Non-registered Holder" means such person or company whose shares are held in the Central Clearing
- 2. and Settlement System and who has notified the Company from time to time through Hong Kong Securities Clearing Company Limited that he/she/it wishes to receive the Corporate Communications). Please complete all your details clearly. 本申請表應由公司股份非登記持有人(「非登記持有人」指所持有的公司股份存放於中央結算及交收系統的人士或公司,透過香港中央結算有限公司不時向公司發出通知,表示欲收取公
- 司通訊)填寫。請 閣下清楚填妥所有資料。
  Any form with more than one box marked "X", with no box marked "X", with no signature or otherwise incorrectly completed will be void. 如在本申請表作出超過一項選擇、或未有作出選擇、或未有簽署、或在其他方面填寫不正確,則本申請表將會作廢。
- For the avoidance of doubt, we do not accept any special instructions given on this Request Form. 為免存疑,任何在本申請表上作出的特別指示,公司將不予處理。

#### Personal Information Collection Statement 收集個人資料聲明:

- "Personal Data" in this statement has the same meaning as "personal data" in the Personal Data (Privacy) Ordinance, Chapter 486 of the laws of Hong Kong ("PDPO").
  本壁明中所指的「個人資料」具有香港法例第486章《個人資料(私隱)條例》(「《私應條例》」)中「個人資料」的涵義。
  Your supply of Personal Data to the Company is on a voluntary basis. If you fail to provide sufficient information, the Company may not be able to process your instructions and/or requests as stated in
- (ii)
- (iii) Your Personal Data may be disclosed or transferred by the Company to its subsidiaries, its share registrar, and/or other companies or bodies for any of the stated purposes, and retained for such period as may be necessary for verification and record purposes. 公司可就任何所說明的用途,將 閣下的個人資料披露或轉移給公司的附屬公司、證券登記處,及/或其他公司或團體,並將在適當期間保留該等個人資料作核實及記錄用途。
- You have the right to request access to and/or correction of your Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction of your Personal Data should be made in writing to the Personal Data Privacy Officer of Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong. 图下有權根據《私隱條例》的條文查閱及/或修改 图下的個人資料。任何該等查閱及/或修改個人資料的要求均須以書面方式向香港中央證券登記有限公司(地址為香港灣仔皇后大道 (iv) 東183號合和中心17M樓)的個人資料私隱主任提出。
- \* Corporate Communications include but are not limited to (a) an annual report; (b) an interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.
- \* 公司通訊包括但不限於:(a) 年度報告;(b) 中期報告;(c) 會議通告;(d) 上市文件;(e) 通函;及(f) 代表委任表格。

### Mailing Label 郵寄標籤

Computershare Hong Kong Investor Services Limited

香港中央證券登記有限公司

Freepost No. 簡便回郵號碼:37 Hong Kong 香港

Please cut the mailing label and stick it on an envelope to return this Request Form to us.

No postage is necessary if posted in Hong Kong.

閣下寄回本申請表格時,請將郵寄標籤剪貼於信封上 如在本港投寄 · 閣下無需支付郵費或貼上郵票。

#### Get in touch with us 與我們聯繫

Send us an enquiry Rate our service 評價 Lodge a complaint 投訴



Contact Us 聯繫我們

www.computershare.com/hk/contact